Dan Hess

Heme/Onc Fellow at Duke by way of @universityofga, @UVaMSTP @lab_owens, @uabimres. Views are mine

[Dan Hess @DHESS280]

@LauraAlderMD Congrats! Well deserved!

[Dan Hess @DHESS280]

@OncodailyLung @DiFedericoMD Important question. Nice work. @DiFedericoMD are there plans for randomized trial to test?

[Dan Hess @DHESS280]

@Eddie_Cliff @MSKCancerCenter If not GELF, what should we be using to determine need for treatment?

[Dan Hess @DHESS280]

@BalazsHalmosMD Thanks for the reply!

[Dan Hess @DHESS280]

@BalazsHalmosMD Cool case, glad patient is doing well. Are you typically serially following ctdna in the metastatic setting like this?

[Dan Hess @DHESS280]

@AndrewKaufmanMD Stick to psychiatry

[Gabriel Aleixo @chefaleixomd]

Tailoring cancer care for older adults isn’t “extra” — it’s better care.
Proud of our team for showing that geriatric oncology can be implemented successfully in the community and meaningfully improve end-of-life outcomes:

[Dan Hess @DHESS280]

@SuyogCancer Ignore me. I just noticed you also listed it

[Dan Hess @DHESS280]

@SuyogCancer We may have another option soon in camrelizumab + rivoceranib based on CARES-310 that was just published

[Dan Hess @DHESS280]

@DrRishabhOnco Thanks for the reply and thanks for all the superb. I learn a ton from your posts!

[Paolo Tarantino @PTarantinoMD]

ADCs: guided missiles, slow chemo infusion, or something else? In our latest free-access commentary, led by Matthew Vogel and just out in @JCO_ASCO, we review the latest evidence on ADCs’ mechanism of action, diving deep into their fascinating complexity. https://t.co/H1OGlAKdHk

[Nature Cancer @NatureCancer]

🔔Take a look at this article now published @NatureCancer !

'Tumor antigens preferentially derive from unmutated genomic sequences in #melanoma and non-small cell #lungcancer'

✏️By Pierre Thibault, Claude Perreault and colleagues

🔗https://t.co/2cjS2j3h81

[Vinay Prasad MD MPH @VPrasadMDMPH]

A commenter writes, "This makes my blood boil with anger."

Learn why he is right about a NIH funded study published in NEJM
https://t.co/1ZSsJF61jZ

[Anish Koka, MD @anish_koka]

I really don’t think people realize how incredibly hard and complex real cancer is to treat.

Oncologists would happily treat their dying patients with this.

It just isn’t true that there’s a simple off the shelf generic that magically cures all cancers.

[UAB Department of Orthopaedic Surgery @UABOrtho]

WELCOME: Dr. Matthew Hess to the Department of Orthopaedic Surgery! Hess is 1 of only 2 specialists trained in pediatric & adult orthopaedic surgical oncology in Alabama.

More: https://t.co/wlU16yItZh

@UABHeersink @uabmedicine @ONealCancerUAB @ChildrensAL @VABIRMINGHAM @UABNews

[Duke Hematologic Malignancies & Cellular Therapy @DukeHMCT]

#myeloMATCH clinical trials are now open at @DukeCancer, using advanced biomarker testing to optimize therapy for patients with #AML & #MDS. An @theNCI precision medicine endeavor led by Duke's own Dr. #HarryErba and Dr. Richard Little of the NCI.

https://t.co/FlZdy89lvS

[Ramy Sedhom, MD, FASCO @ramsedhom]

A positive trial for cancer cachexia - a very distressing symptom to patients and caregivers! Congrats to my bud @MDRoeland for being an @NEJM author

[Dan Hess @DHESS280]

@ASCO Congrats @GrantWilliamsMD! A much deserved honor!

[Vinay Prasad MD MPH @VPrasadMDMPH]

Less than half of cancer drugs approved based on a surrogate endpoint are ever found to improve survival in their entire lifecycle.

https://t.co/P7mdPYc8FG